[99mTc] Demotate 2 in the detection of sst2-positive tumours: A preclinical comparison with [111In]DOTA-tate

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 33, Issue 7, 2006, Pages 831-840

  Maina, Theodosia ^a   Nock, Berthold A ^a   Cordopatis, Paul ^b   Bernard, Bert F ^c   Breeman, Wout A P ^c   Van Gameren, Arthur ^c   Van Den Berg, Ria ^c   Reubi, Jean Claude ^d   Krenning, Eric P ^c   De Jong, Marion ^c  

^a INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

DOTA; Radiolabelled Tyr 3 octreotate; sst2 targeting; Tetraamine

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; DEMOTATE 2 TECHNETIUM 99M; INDIUM 111; PENTETREOTIDE; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; BRAIN TUMOR; CHEMICAL ANALYSIS; DIAGNOSTIC IMAGING; DRUG EXCRETION; DRUG UPTAKE; HUMAN; HUMAN TISSUE; INTERNALIZATION; LABELING INDEX; NONHUMAN; RADIOCHEMISTRY; RAT; SCINTIGRAPHY; TISSUE DISTRIBUTION;

ANIMALS; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; MALE; METABOLIC CLEARANCE RATE; NEOPLASM PROTEINS; OCTREOTIDE; ORGAN SPECIFICITY; ORGANOMETALLIC COMPOUNDS; ORGANOTECHNETIUM COMPOUNDS; PANCREATIC NEOPLASMS; PEPTIDES, CYCLIC; RADIOPHARMACEUTICALS; RATS; RATS, INBRED LEW; RECEPTORS, SOMATOSTATIN; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; TUMOR MARKERS, BIOLOGICAL;

EID: 33745582887     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0068-8     Document Type: Article

References (31)

1. Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging. Semin Nucl Med 2002;32:84-91
2. Breeman WAP, de Jong M, Kwekkeboom DJ, Valkema R, Bakker WH, Kooij PPM, et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med Mol Imaging 2001;28:1421-1429
3. de Jong M, Kwekkeboom D, Valkema R, Krenning EP. Radiolabeled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002. Eur J Nucl Med Mol Imaging 2003;30:463-469
4. 5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med Mol Imaging 2000;27:273-282
5. 90Y-labeled somatostatin analogs. J Nucl Med 2005;46:13S-17S
6. Kwekkeboom DJ, Müller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005;46:62S-66S
7. Krenning EP, Valkema R, Kwekkeboom DJ, de Herder WW, van Eijck CHJ, de Jong M, et al. Molecular imaging as in vivo molecular pathology for gastroenteropancreatic neuroendocrine tumors: implications for follow-up after therapy. J Nucl Med 2005;46:76S-82S
8. 99mTc-labeled small peptides as diagnostic radiopharmaceuticals. Chem Rev 1998;58:437-441
9. Schibli R, Schubiger PA. Current use and future potential of organometallic radiopharmaceuticals. Eur J Nucl Med Mol Imaging 2002;29:1529-1542
10. Shih WJ, Hirschowitz E, Bensadoun E, Woodring J, Ryo YU, Kraman S. Biodistribution on Tc-99 m labeled somatostatin receptor-binding peptide (Depreotide, NeoTec) planar and SPECT studies. Ann Nucl Med 2002;16:213-219
11. Shih WJ, Kiefer V. Radiation therapy of changes secondary to lung cancer and pneumonectomy on bone and Tc-99 m depreotide imaging. Clin Nucl Med 2003;28:419-420
12. 111m-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med 2003;44:708-716
13. 99mTc-EDDA/HYNIC-TOC scintigraphy in oncological diagnostics: a preliminary communication. Eur J Nucl Med Mol Imaging 2003;30:1402-1406
14. 0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization? J Nucl Med 2005;46:1561-1569
15. 3] octreotate analogue for the detection of somatostatin receptor-positive tumours: synthesis and preclinical results. Eur J Nucl Med Mol Imaging 2002;29:742-753
16. 99mTc-Demotate 1: first data in tumour patients-results of a pilot/phase I study. Eur J Nucl Med Mol Imaging 2003;30:1211-1219
17. 3]octreotide: an intrapatient comparison of two novel technetium-99 m labeled tracers for somatostatin receptor scintigraphy. Cancer Biother Radioph 2004;19:73-79
18. Mantegazzi D, Ianoz E, Lerch P, Nicolò F, Chapuis G. Preparation and crystal structure of polymeric lithium[diox-oTc(V)-tetraazaundecane]- bis(trifluoromethanesulfonate) complex. Inorg Chim Acta 1990;176:99-105
19. +. Inorg Chem 1988;27:4127-4130
20. Bläuenstein P, Pfeiffer G, Schubiger PA, Anderegg G, Zollinger K, May K, Proso Z, Ianovici E, Lerch P. Chemical and biological properties of a cationic Tc-tetraamine complex. Int J Appl Radiat Isot 1985;36:315-317
21. Prakash S, Went MJ, Blower PJ. Cyclic and acyclic polyamines as chelators of rhenium-186 and rhenium-188 for therapeutic use. Nucl Med Biol 1996;23:543-549
22. 3]octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 2001;92:628-633
23. 0]octreotide in patients. Eur J Nucl Med Mol Imaging 2001;28:1319-1325
24. 177Lu at high specific activities. Eur J Nucl Med Mol Imaging 2003;30:917-920
25. 3]octreotide by somatostatin receptor-positive cells in vitro and in vivo: implications for somatostatin receptor-targeted radio-guided surgery. Proc Assoc Am Phys 1999;111:63-69
26. Bernard BF, Krenning E, Breeman WAP, Visser TJ, Bakker WH, Srinivasan A, et al. Use of the rat pancreatic CA20948 cell line for the comparison of radiolabeled peptides for receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Commun 2000;21:1079-1085
27. Taylor JE, Theveniau MA, Bashirzadeh R, Reisine T, Eden PA. Detection of somatostatin receptor subtype 2 (SSTR2) in established tumors and tumor cell lines: evidence for SSTR2 heterogeneity. Peptides 1994;15:1229-1236
28. Froidevaux S, Hintermann E, Török M, Mäcke HR, Beglinger C, Eberle AN. Differential regulation of somatostatin receptor type 2 (sst 2) expression in AR4-2J tumor cells implanted into mice during octreotide treatment. Cancer Res 1999;59:3652-3657
29. Duncan JR, Stephenson MT, Wu HP, Anderson CJ. Indium-111- diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes. Cancer Res 1997;57:659-671
30. 1-octreotide in vivo. Bioconjugate Chem 1998;9:662-670
31. 111In-DTPA-conjugated peptides. Nucl Med Biol 2001;28:761-768